U.S. Pharmacovigilance Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. pharmacovigilance market highlights
- The U.S. pharmacovigilance market generated a revenue of USD 2,241.0 million in 2025 and is expected to reach USD 2,981.3 million by 2033.
- The U.S. market is expected to grow at a CAGR of 3.4% from 2026 to 2033.
- In terms of segment, phase iv was the largest revenue generating product life cycle in 2025.
- Phase I is the most lucrative product life cycle segment registering the fastest growth during the forecast period.
Pharmacovigilance market data book summary
| Market revenue in 2025 | USD 2,241.0 million |
| Market revenue in 2033 | USD 2,981.3 million |
| Growth rate | 3.4% (CAGR from 2026 to 2033) |
| Largest segment | Phase iv |
| Fastest growing segment | Phase I |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre Clinical, Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica |
Other key industry trends
- In terms of revenue, U.S. accounted for 26.1% of the global pharmacovigilance market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. pharmacovigilance market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 821.2 million by 2033.
The U.S. held the dominant share of the pharmacovigilance market owing to a high incidence of Adverse Drug Reactions (ADRs) in this region due to high drug consumption. In 2007, U.S. FDA implemented Risk Evaluation and Mitigation Strategy (REMS) Act to unveil the potential risks associated with a drug following a series of drug safety-related events.
After the implementation of this act, all manufacturers of drugs were required to submit REMS to the FDA. Drugs that fail to follow the REMS provision could be considered misbranded. Moreover, the U.S. FDA launched Sentinel Initiative in 2008, a national electronic system that tracks the safety of drugs and medical devices.
The increasing geriatric population and rising prevalence of chronic diseases have resulted in the rise in demand for the development of novel drugs, which in turn is expected to boost the demand for clinical trials in the U.S. In addition, the presence of various biotechnology funding initiatives in this region is expected to significantly increase the volume of clinical trials, thereby propelling demand for Pharmacovigilance (PV) services over the forecast period.
No credit card required*
Publish Date: Jun 05, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Pharmacovigilance Market Scope
Pharmacovigilance Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| International Business Machines Corp | View profile | 282,200 | One New Orchard Road, Armonk, NY, United States, 10504 | www.ibm.com |
| Wipro Ltd ADR | View profile | 244,707 | Sarjapur Road, Doddakannelli, Bangalore, KA, India, 560 035 | www.wipro.com |
| Accenture PLC Class A | View profile | 742,000 | 1 Grand Canal Square, Grand Canal Harbour, Dublin, Ireland, 2 | www.accenture.com |
| Cognizant Technology Solutions Corp Class A | View profile | 344,400 | 300 Frank West Burr Boulevard, Suite 36, 6th Floor, Teaneck, NJ, United States, 07666 | www.cognizant.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.parexel.com |
| ArisGlobal | View profile | 1001-5000 | Coral Gables, Florida, United States, North America | www.arisglobal.com |
| Capgemini SE | View profile | 340,400 | 11 rue de Tilsitt, Paris, France, 75017 | www.capgemini.com |
U.S. Pharmacovigilance Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmacovigilance Market Outlook will help companies and investors design strategic landscapes.
Phase Iv was the largest segment with a revenue share of 80.0% in 2025.
Horizon Databook has segmented the U.S. pharmacovigilance market based on pre clinical, phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. held the dominant share of the pharmacovigilance market owing to a high incidence of Adverse Drug Reactions (ADRs) in this region due to high drug consumption. In 2007, U.S. FDA implemented Risk Evaluation and Mitigation Strategy (REMS) Act to unveil the potential risks associated with a drug following a series of drug safety-related events.
After the implementation of this act, all manufacturers of drugs were required to submit REMS to the FDA. Drugs that fail to follow the REMS provision could be considered misbranded. Moreover, the U.S. FDA launched Sentinel Initiative in 2008, a national electronic system that tracks the safety of drugs and medical devices.
The increasing geriatric population and rising prevalence of chronic diseases have resulted in the rise in demand for the development of novel drugs, which in turn is expected to boost the demand for clinical trials in the U.S. In addition, the presence of various biotechnology funding initiatives in this region is expected to significantly increase the volume of clinical trials, thereby propelling demand for Pharmacovigilance (PV) services over the forecast period.
- U.S. Pharmacovigilance Market Product Life Cycle Outlook (Revenue, USD Million , 2021-2033)
- Pre Clinical
- Phase I
- Phase II
- Phase III
- Phase IV
- U.S. Pharmacovigilance Market Service Provider Outlook (Revenue, USD Million , 2021-2033)
- In House
- Contract outsourcing
- U.S. Pharmacovigilance Market Type Outlook (Revenue, USD Million , 2021-2033)
- Spontaneous reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
- U.S. Pharmacovigilance Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceuticals
- Biotechnology Companies
- Medical Device Manufacturers
- Others
- U.S. Pharmacovigilance Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Neurology
- Cardiology
- Respiratory Systems
- Others
- U.S. Pharmacovigilance Market Process Flow Outlook (Revenue, USD Million , 2021-2033)
- Case Data Management
- Signal Detection
- Risk Management System
Reasons to subscribe to Pharmacovigilance Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmacovigilance Market Outlook databook
- Our clientele includes a mix of Pharmacovigilance Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Pharmacovigilance Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Pharmacovigilance Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Pharmacovigilance Market, 2021-2033 (US$M)
U.S. pharmacovigilance market statistics, by product life cycle, 2021-2033 (US$M)
